HealthTech M&A Multiples March 2026: Current Trends and Variables driving valuations

As of March 2026, the HealthTech M&A landscape has shifted from the "growth at all costs" frenzy of the early 2020s to a regime of Industrial Maturity. Valuations have bifurcated: while general SaaS multiples remain disciplined, a new "X-Factor" premium has emerged for companies that effectively integrate AI into clinical workflows and possess proprietary data moats.

The current market is defined by "Regulatory Darwinism," where compliance with the EU AI Act (enforced as of March 2026) and MDR/IVDR standards has become a primary driver of enterprise value.

1. Current M&A Valuation Multiples (Q1 2026)

Valuations are currently categorized by the "Rule of 40+Data," rewarding companies that balance growth with profitability and defensible data assets.

Premium AI & Data Platforms

EV / Revenue Multiple 6.0x – 12.0x+

EV / EBITDA Multiple 15x – 20x+

Key Valuation Drivers - Proprietary clinical datasets; validated AI; Rule of 40 performance.

Value-Based Care (VBC)

EV / Revenue Multiple 5.5x – 7.5x

EV / EBITDA Multiple 12x – 15x

Key Valuation Drivers - Demonstrable ROI for payers; high population health impact.

General HealthTech SaaS

EV / Revenue Multiple 4.0x – 6.0x

EV / EBITDA Multiple 10x – 13x

Key Valuation Drivers - Predictable unit economics; stable retention; B2B integration.

MedTech / Hardware

EV / Revenue Multiple 3.5x – 5.5x

EV / EBITDA Multiple 11x – 14x

Key Valuation Drivers - MDR/IVDR compliance; "compliance moats"; high barriers to entry.

Sub-scale / Unprofitable

EV / Revenue Multiple 2.5x – 4.0x

EV / EBITDA Multiple N/A

Key Valuation Drivers - High burn; lack of clear defensibility; "fire sale" territory.

2. Key Variables Driving Valuations in 2026

A. The "Compliance Moat" (MDR & EU AI Act)

As of March 2026, the full enforcement of the EU AI Act for "high-risk" medical systems has created a binary filter for investors.

The Premium: Assets with existing MDR/IVDR certifications and "glass box" (transparent) AI models command a 20-30% premium because they represent immediate market entry for US strategics.
The Discount: Non-compliant assets face a 18–24 month regulatory bottleneck, leading to significant valuation compression.

B. The AI "X-Factor" and Productivity

Buyers are no longer paying for "AI-enabled" labels. Valuations are now driven by ARR per FTE (Full-Time Equivalent).

Companies that use AI to achieve software-like margins (e.g., in RCM, coding, or drug discovery) are seeing their multiples expand.

AI-First Drug Discovery remains a high-outlier segment, often trading at 8.0x – 15.0x revenue due to the "bio-bucks" potential and the looming pharmaceutical patent cliff (e.g., Eliquis and Keytruda losing exclusivity).

C. Shift to "Unsexy" Infrastructure

Smart capital has moved from consumer-facing apps to the "plumbing" of healthcare.

Interoperability: Platforms supporting FHIR R4, TEFCA alignment, and clean DICOM support for imaging are highly sought after by PE-backed HCIT consolidators.

Workflow Integration: "Point solutions" are being discounted in favor of "systems of action" that sit directly within the clinician's EHR workflow.

3. Macro Trends Shaping the March 2026 Market

The "Trust Gap" is Closing: While HealthTech 2.0 stocks still trade at a 10-15% discount compared to general Cloud SaaS (Bessemer HealthTech Index), the gap is narrowing as companies prove sustainable 60%+ growth with positive FCF.

Strategic vs. Financial Buyers: Corporate strategics (e.g., Abbott, Siemens, Roche) are currently paying 25–40% higher multiples than Private Equity firms to fill R&D gaps and secure "compliance moats."

The "Use It or Lose It" Dynamic: Many 2021-vintage PE funds are reaching the end of their investment periods, leading to an intensified deal volume in Q1 and Q2 2026 as they deploy remaining dry powder.

Note on Value-Based Care (VBC): After a rocky 2024-25, VBC is seeing a "comeback" multiple expansion. Success is now measured by the ability to manage high-cost chronic conditions (Oncology, Cardiology) using AI-driven predictive analytics to reduce hospital readmissions.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]